Skip to content

Jordi Ortuño

9 papers in the library · 732 citations · publishing 1999-2005

Papers

Sort Most recent Most cited

Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Clinical Pharmacokinetics 2005 Mireia Segura, Magí Farré, Simona Pichini et al.

3,4-Methylenedioxymethamphetamine (MDMA) is a synthetic amphetamine derivative typically used for recreational purposes. The participation of cytochrome P450 (CYP) 2D6 in the oxidative metabolism of MDMA may suggest an increased risk of acute toxicity in CYP2D6 poor metabolisers. This study was aimed at assessing the contribution of CYP2D6 to MDMA disposition in vivo using paroxetine as a...

The rewarding properties of MDMA are preserved in mice lacking µ‐opioid receptors

European Journal of Neuroscience July 15, 2004 Patricia Robledo, Victoria Mendizábal, Jordi Ortuño et al. 40 citations

Abstract The involvement of µ‐opioid receptors in the rewarding properties of MDMA was explored in µ‐opioid receptor knockout mice using the conditioning place preference paradigm. The associated release of dopamine in the nucleus accumbens was investigated by in vivo microdialysis. A significant rewarding effect of MDMA (10 mg/kg, i.p.) was observed in both wild‐type and µ‐opioid receptor...

DOI: 10.1111/j.1460-9568.2004.03532.x (opens in new tab) MDMA Nucleus accumbens Conditioned place preference Dopaminergic +6

Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Psychopharmacology May 2004 M Farré, Rafael de la Torre, Brian O Mathúna et al.

3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") is increasingly used by young people for its euphoric and empathic effects. MDMA presents non-linear pharmacokinetics, probably by inhibition of cytochrome P450 isoform 2D6. Users are known to often take more than one dose per session. This practice could have serious implications for the toxicity of MDMA. To evaluate the pharmacological...

Cell‐Mediated Immune Response in MDMA Users After Repeated Dose Administration

Annals of the New York Academy of Sciences June 1, 2002 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 58 citations

A bstract : Acute administration of 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) produces time‐dependent immune dysfunction in humans. Recreational use of MDMA generally includes repeated drug consumption, often in association with other drugs, such as alcohol and cannabis. In the laboratory setting, repeated MDMA administration to healthy MDMA consumers produced a time‐dependent immune...

DOI: 10.1111/j.1749-6632.2002.tb04183.x (opens in new tab) MDMA Immune system Pharmacology Administration probate law +1

Sweat Testing of MDMA with the Drugwipe(R) Analytical Device: A Controlled Study with Two Volunteers

Journal of Analytical Toxicology March 1, 2001 Roberta Pacifici, Magı́ Farré, Simona Pichini et al. 50 citations

Rapid on-site tests for the analysis of drugs of abuse in unconventional specimens (e.g., sweat) have recently been developed. Two healthy volunteers familiar with the effects of methylenedioxymethamphetamine (MDMA) were given 100 mg of the drug as a single oral dose. MDMA and its main metabolite 4-hydroxy-3-methoxymethamphetamine (HMMA) were determined in plasma and urine by gas...

Pharmacology of MDMA in Humans

Annals of the New York Academy of Sciences September 1, 2000 Rafael de la Torre, Magı́ Farré, Pere N. Roset et al. 178 citations

Abstract MDMA given at recreational doses (range tested 50 to 150 mg) to healthy volunteers, produced mydriasis and marked increases in systolic and diastolic blood pressure, heart rate, and pupillary diameter. MDMA induced changes on oral temperature. The time course of this observation was biphasic, as a slight decrease at 1 h and a slight increase at 2 and 4 h were observed. MDMA induced a...

Immunomodulating Activity of MDMA

Annals of the New York Academy of Sciences September 1, 2000 Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al. 44 citations

Abstract MDMA (3,4‐methylenedioxymethamphetamine) use can cause neurochemical, behavioral and endocrine alterations, similar to those produced by exposure to acute stress, suggesting its potential as a “chemical stressor.” It is known that stressful stimuli can produce a depression of immune function and an alteration in immune cells distribution. In vitro exposure to MDMA resulted in a...

DOI: 10.1111/j.1749-6632.2000.tb05198.x (opens in new tab) MDMA Immune system Endocrinology Neurochemical +5

Non‐linear pharmacokinetics of MDMA (‘ecstasy’) in humans

British Journal of Clinical Pharmacology February 1, 2000 Rafael de la Torre, Magı́ Farré, Jordi Ortuño et al.

Aims 3,4‐Methylenedioxymethamphetamine (MDMA, commonly called ecstasy) is a synthetic compound increasingly popular as a recreational drug. Little is known about its pharmacology, including its metabolism and pharmacokinetics, in humans in controlled settings. A clinical trial was designed for the evaluation of MDMA pharmacological effects and pharmacokinetics in healthy volunteers. Methods A...

Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Journal of Pharmacology and Experimental Therapeutics July 1, 1999 M. Mas, M. Farré, Rafael de la Torre et al. 362 citations

The cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") were assessed in a double-blind, randomized, crossover, and controlled (placebo and amphetamine) clinical trial. Eight men with experience in the recreational use of MDMA participated in four 10-h experimental sessions with a 1-week washout period. Single oral doses of 125...